SW
BIB icon

SVB Wealth’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

SVB Wealth’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,500
Closed -$142K – 828
2021
Q3 		$142K Hold
1,500
– – ﹤0.01% 927
2021
Q2 		$147K Hold
1,500
– – ﹤0.01% 908
2021
Q1 		$125K Hold
1,500
– – ﹤0.01% 858
2020
Q4 		$129K Hold
1,500
– – ﹤0.01% 784
2020
Q3 		$105K Hold
1,500
– – ﹤0.01% 673
2020
Q2 		$108K Hold
1,500
– – ﹤0.01% 574
2020
Q1 		$69K Hold
1,500
– – ﹤0.01% 508
2019
Q4 		$93K Buy
+1,500
New +$80K ﹤0.01% 597

Other funds holding BIB

OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SVB Wealth's BIB Position: Q4 2021 in Review

SVB Wealth sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2021, closing a stake of 1,500 shares — an estimated $142K sold.

SVB Wealth first reported a position in BIB in Q4 2019 and held it in 8 quarters. The position peaked at $147K in Q2 2021. 37 funds tracked by Wall St. Rank hold BIB as of Q4 2021.

  • SVB Wealth reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2021 after selling out during the quarter.
  • SVB Wealth sold 1,500 ProShares Ultra NASDAQ Biotechnology shares in Q4 2021, an estimated $142K.
  • SVB Wealth first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2019 and held it in 8 quarters.
  • SVB Wealth's ProShares Ultra NASDAQ Biotechnology position peaked at $147K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2021.

Based on SVB Wealth's 13F filing for Q4 2021, filed 15 Feb 2022.